Media coverage
1
Media coverage
Title Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial Media name/outlet The Lancet Media type Other Date 29/04/2022 URL https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00093-5/fulltext Persons Dieuwke Broekstra